期刊文献+

运用组织芯片技术检测COX-2在结直肠癌中的表达及其临床意义 被引量:3

Expression of COX-2 protein in colorectal carcinoma and the clinical implication
下载PDF
导出
摘要 目的探讨结直肠癌组织中COX-2的表达及其与各临床病理因素的关系,评价COX-2在结直肠癌预后判断中的价值。方法应用组织芯片技术结合免疫组织化学SABC法,检测126例早中期结直肠癌组织中COX-2的表达情况,回顾性分析COX-2与各临床病理因素及预后之间的关系。结果根据免疫组化染色强度,所有病例被分为COX-2高表达组和低表达组,其中高表达组有32例(25.4%),低表达组有94例(74.6%)。COX-2在结直肠癌中表达情况与年龄、性别、肿瘤大小、肿瘤部位、组织学类型、浸润深度、淋巴是否转移、Dukes分期均无相关。然而,高表达的COX-2与肿瘤复发、特别是血行转移显著相关(P<0.05)。两组之间生存率具有显著差异(P=0.0067),COX-2高表达组术后五年生存率显著低于低表达组。多因素回归模型分析结果显示,在潜在的预后因素中(年龄、性别、肿瘤大小、肿瘤部位、组织学类型、淋巴是否转移、Dukes分期、COX-2表达),COX-2表达和Dukes分期可作为是结直肠癌根治术后独立预后因素,COX-2的检测可作为结直肠癌患者预后判断的一个有价值的指标。结论高表达的COX-2与肿瘤复发、特别是血行转移显著相关,COX-2的检测可作为结直肠癌患者预后判断的一个有价值的指标。应用组织芯片高效检测临床组织样本具有快速、方便、经济、准确的优点。 Objective To investigate the relationship between COX-2 expression and the clinicopathological factors in colorectal carcinoma and assess the prognostic value of COX-2 detection. Methods Tissue microarray and immunohistochemistry by SABC method was employed for detecting COX-2 expression in 126 patients with advanced colorectal cancer, and the relationship of COX-2 expression with the clinicopathological features and prognosis of the patients was retrospectively analyzed. Results The patients were divided into two groups of low and high COX-2 groups according to the grade and extent of COX-2 expression. High COX-2 expression was detected in 32 (25.4%) cases, and low expression in 94 (74.6%) cases. No significant correlation was noted between COX-2 expression and the patients' age, sex, tumor size, tumor location, histological type, lymphatic-node metastasis and Dukes' classification, but high COX-2 expression was strongly correlated with tumor recurrence and especially with blood-borne metastasis (P〈0.05). The survival rate without tumor recurrence for high- and low-COX-2 groups was assessed by the Kaplan-Meier method and compared by log-rank test, which revealed significant difference between the two groups (P=0.0067). Multivariate analysis for all patients suggested that among the 8 prognostic factors (age, sex, tumor size, tumor location, histological type, lymphatic-node metastasis, Dukes' stage, and COX-2 expression), Dukes' stage and COX-2 expression was the independent significant factor related to disease-free survival. Conclusion The expression of COX-2 is strongly correlated with recurrence ofcolorectal cancer, especially with blood-bome metastasis. COX-2 is an independent factor for prognostic evaluation of the patients, and tissue microarray allows rapid, convenient, economic and accurate COX-2 detection for large-scale application.
出处 《第一军医大学学报》 CSCD 北大核心 2005年第12期1524-1528,共5页 Journal of First Military Medical University
关键词 组织芯片 COX-2 结直肠癌 预后 COX-2 tissue microarray colorectal carcinoma prognosis
  • 相关文献

参考文献6

二级参考文献63

  • 1Kallioniemi OP, Wagner U, Kononen J, Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genetics 2001; 10:657-662
  • 2Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P,Leighton S, Torhors J, Mihatsch MJ, Sauter G, Kalioniemi OP.Tissue microarray for high-throughput molecular profiling of tumor specimens. Nature Med 1998; 4:844-847
  • 3Moch H, Kononen T, Kallioniemi OP, Sauter G. Tissue microarray: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 2001 ;8:14-20
  • 4Rimm DL, Camp RL, Charette LA, Costa J, Olsen DA, Reiss M.Tissue microarray: a new technology for amplification of tissue resources. CancerJ 2001 ;7:24-31
  • 5Nagle RB. New molecular approaches to tissue analysis. J Histochem Cytochem 2001 ;49:1063-1064
  • 6Bubendorf L, Nocito A, Moch H, Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 2001; 195: 72-79
  • 7Yang GP, Ross DT, Kuang WW, Brown PO, Weigel RJ. Combining SSH and cDNA microarrays for rapid identification of differentially expressed genes. Nucleic Acids Res 1999 ;27:1517-1523
  • 8Wang K, Gan L, Jeffery E, Gayle M, Gown AM, Skelly M, Nelson PS, Ng WV, Schummer M, Hood L, Mulligan J. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 1999;229:101-108
  • 9Khan J, Saal LH, Bittner ML, Chen Y, Trent JM, Meltzer PS.Expression profiling in cancer using eDNA microarrays. Electrophoresis1999; 20: 223-229
  • 10Khan J, Simon R, Bittner N, Chen Y, Leighton SB, Pohida T, Smith PD, Jiang Y, Gooden GC, Trent JM, Meltzer PS. Gene expression profiling of alveolar rhabdomyosarcoma with cDNA microarrays.Cancer Res 1998 ;58:5009-5013

共引文献176

同被引文献29

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部